Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

PragmaTIL Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors

Coordinator
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio), Spain
Runs
1 April 2023 to 31 March 2028
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
13 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101104684

What the project is doing

In the project's own words, from its summary on CORDIS.

The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy.

This improved tolerability will achieve a better clinical management of patients and enhance their quality of life, both of which represent major barriers for applying this treatment. The objectives of PragmaTIL are: i) To determine whether TIL-ACT using IL-2 analog ANV600 reduces the frequency of Grade ≥3 study-related non-hematological toxicities

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainCoordinator
Region HovedstadenHillerodDenmarkParticipant
Asphalion SLBarcelonaSpainParticipant
Banc De Sang I TeixitsBarcelonaSpainThird party
Bcn Health Economics & Outcomes Research SLBarcelonaSpainParticipant
Fundacion Bancaria Caixa D Estalvis I Pensions De Barcelona La CaixaBarcelonaSpainParticipant
Innovandum Health SLValenciaSpainParticipant
Citoyens Et RechercheParisFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
UnicancerParisFranceParticipant
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical CenterRamat GanIsraelParticipant
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Region StockholmStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI